CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”. The company is also transforming its largest laboratory space into a centre of excellence for oligonucleotide development by remodelling it to create efficient working spaces for existing and new capabilities.

Drug development services supplier CatSci has acquired its UK compatriot Reach Separations. No financial details were disclosed but the company said that this deal was supported by Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments. The whole of the Reach Separations will transfer and the companies will be fully integrated.

Under a newly signed partnership, AGC Pharma Chemicals and CatSci will combine to offer the former’s expertise in GMP manufacturing from development and manufacturing through to commercial with the latter’s in chemical development, analytical development, crystallisation and solid form, pre-formulation and HPAPI capabilities.

CatSci has made a “significant” investment to support the development of oligonucleotide capability at its site in Cardiff, UK. This follows recent investment in the firm by Keensight Capital to support its strategic growth plans.

Drug development firm CatSci has secured £4.5 million of investment from ‘alternative lender’ Boost & Co. This is described as a continuation of the Cardiff-based firm’s £3 million investment, which was started in 2021.

CatSci will use the funding to install new equipment and expand its laboratories by adding capabilities in chemical and analytical development, material science, product formulation and GMP analytical testing in both Cardiff and London. Some will be used to refinance its existing debt.